CA2399584A1 - Antagonistes de recepteur de tachykinine non peptidique - Google Patents

Antagonistes de recepteur de tachykinine non peptidique Download PDF

Info

Publication number
CA2399584A1
CA2399584A1 CA002399584A CA2399584A CA2399584A1 CA 2399584 A1 CA2399584 A1 CA 2399584A1 CA 002399584 A CA002399584 A CA 002399584A CA 2399584 A CA2399584 A CA 2399584A CA 2399584 A1 CA2399584 A1 CA 2399584A1
Authority
CA
Canada
Prior art keywords
phenyl
ylmethyl
indol
alkyl
benzofuran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002399584A
Other languages
English (en)
Inventor
David Christopher Horwell
Russell Andrew Lewthwaite
Martin Clive Pritchard
Jennifer Raphy
Hubert Barth
Klaus Steiner
Bernd Schiefermayr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00103665A external-priority patent/EP1127875A1/fr
Application filed by Individual filed Critical Individual
Publication of CA2399584A1 publication Critical patent/CA2399584A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La présente invention concerne des composés antagonistes de récepteur de tachykinine de formule (I), dans laquelle R, m, X, R1, R2, n, Y, R3, R4, R5 et R6 sont tels que décrits dans la description de l'invention. Ces composés sont des agents utiles pour traiter des états associés à une néovascularisation aberrante, telle que la polyarthrite rhumatoïde, l'athérosclérose et la croissance de cellules tumorales.
CA002399584A 1999-12-22 2000-12-21 Antagonistes de recepteur de tachykinine non peptidique Abandoned CA2399584A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17154099P 1999-12-22 1999-12-22
US60/171,540 1999-12-22
EP00103665.6 2000-02-22
EP00103665A EP1127875A1 (fr) 2000-02-22 2000-02-22 Procédé de préparation de l'ester méthylique de l'alpha-diméthylaminométhyl-tryptophane
PCT/EP2000/013349 WO2001046176A2 (fr) 1999-12-22 2000-12-21 Antagonistes de recepteur de tachykinine non peptidique

Publications (1)

Publication Number Publication Date
CA2399584A1 true CA2399584A1 (fr) 2001-06-28

Family

ID=26070578

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002399584A Abandoned CA2399584A1 (fr) 1999-12-22 2000-12-21 Antagonistes de recepteur de tachykinine non peptidique

Country Status (18)

Country Link
EP (1) EP1244653A1 (fr)
JP (1) JP2003518111A (fr)
KR (1) KR20020062364A (fr)
CN (1) CN1413206A (fr)
AP (1) AP2002002556A0 (fr)
AU (1) AU2370801A (fr)
BG (1) BG106804A (fr)
BR (1) BR0016626A (fr)
CA (1) CA2399584A1 (fr)
IL (1) IL150203A0 (fr)
IS (1) IS6395A (fr)
MA (1) MA26854A1 (fr)
MX (1) MXPA02006282A (fr)
NO (1) NO20022942D0 (fr)
OA (1) OA12129A (fr)
PL (1) PL357650A1 (fr)
SK (1) SK8862002A3 (fr)
WO (1) WO2001046176A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010516734A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンまたはｒ（−）−２，４−ジアミノ−５−（２，３−ジクロロフェニル）−６−フルオロメチルピリミジンを含む医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004494A1 (fr) * 1992-08-13 1994-03-03 Warner-Lambert Company Antagonistes de tachykinine
US6472418B1 (en) * 1998-12-18 2002-10-29 Warner-Lambert Company Non-peptide NK1 receptors antagonists

Also Published As

Publication number Publication date
OA12129A (en) 2006-05-05
NO20022942L (no) 2002-06-19
MA26854A1 (fr) 2004-12-20
IL150203A0 (en) 2002-12-01
BR0016626A (pt) 2002-11-05
CN1413206A (zh) 2003-04-23
WO2001046176A2 (fr) 2001-06-28
KR20020062364A (ko) 2002-07-25
JP2003518111A (ja) 2003-06-03
AP2002002556A0 (en) 2002-06-30
MXPA02006282A (es) 2004-09-06
SK8862002A3 (en) 2002-11-06
EP1244653A1 (fr) 2002-10-02
PL357650A1 (en) 2004-07-26
WO2001046176A3 (fr) 2002-07-04
AU2370801A (en) 2001-07-03
IS6395A (is) 2002-05-24
NO20022942D0 (no) 2002-06-19
BG106804A (en) 2003-03-31

Similar Documents

Publication Publication Date Title
CN111741769B (zh) 一种多功能化合物、其制备方法及其在医药上的应用
CA2894016C (fr) Modulateurs du recepteur gamma orphelin associe au retinoide (ror?) destines au traitement de maladies auto-immunes et inflammatoires
AU698239B2 (en) Tachykinin antagonists
AU641535B2 (en) Serotonin 5HT1A agonists
EP2927231B1 (fr) Composés imidazopyridine
KR101733180B1 (ko) 신규 1-아릴-3-아자바이사이클로［3.1.0］헥산：제조 방법 및 신경 정신 질환 치료를 위한 용도
JP2006501236A (ja) ムスカリン性レセプター拮抗薬としてのフルオロおよびスルホニルアミノ含有３，６−二置換アザビシクロ（３．１．０）ヘキサン誘導体
PL166403B1 (pl) Sposób wytwarzania N-podstawionych pochodnych imidazolu lub pirymidyny PL PL PL PL PL PL
JP2001500850A (ja) 非―ペプチドボンベシン受容体アンタゴニスト
WO1996038420A1 (fr) Derives de l'indazole a groupe amino monocyclique
EP2188253B8 (fr) Dérivés de l'indol-2-one disubstitués en 3, leur préparation et leur application en thérapeutique
EP1717226B1 (fr) Dérivés de la amide du octan 5-amino-4-hydroxy-8-(1h-indol-5-yl) en tant que inhibiteurs du rénin pour le traitement de la hypertension
JPH10501803A (ja) チアゾリジン誘導体、それらの製造及びそれらを含有する薬物
RU2185375C2 (ru) Ациламиноалкениленамидные производные, способы их получения и фармацевтическая композиция на их основе
KR20120099457A (ko) 디아실글리세롤 아실트랜스퍼라제의 억제제
CA2550958A1 (fr) Derives d'ornithine utilises comme agonistes ou antagonistes de la prostaglandine e<sb>2</sb>
JPH07500604A (ja) 高血圧治療用エチルアラニンアミノジオール化合物
JP2002533338A (ja) 非ペプチドｎｋ１レセプターアンタゴニスト
CA2399584A1 (fr) Antagonistes de recepteur de tachykinine non peptidique
CZ289080B6 (cs) N-Substituovaný azabicykloheptanový derivát, způsob jeho výroby a pouľití
WO1999032459A1 (fr) Inhibiteurs de la chymase
WO2021129629A1 (fr) Inhibiteur de l'amplificateur de l'homologue zeste 2 et son utilisation
FR2665702A1 (fr) Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
JP2006188505A (ja) インドール類の製造方法および製造中間体
FR2925051A1 (fr) Derives d'azetidines,leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
FZDE Discontinued